Compugen Ltd. – Product Pipeline Review

Global Markets Direct’s, ‘Compugen Ltd. – Product Pipeline Review – 2016’, provides an overview of the Compugen Ltd.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Compugen Ltd., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.


The report provides a snapshot of the pipeline therapeutic landscape of Compugen Ltd.

The report provides overview of Compugen Ltd. including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Compugen Ltd.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Compugen Ltd.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Compugen Ltd.’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Compugen Ltd.

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Compugen Ltd.’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Compugen Ltd. Snapshot 6

Compugen Ltd. Overview 6

Key Information 6

Key Facts 6

Compugen Ltd. - Research and Development Overview 7

Key Therapeutic Areas 7

Compugen Ltd. - Pipeline Review 10

Pipeline Products by Stage of Development 10

Pipeline Products - Monotherapy 11

Pipeline Products - Out-Licensed Products 12

Out-Licensed Products/Combination Treatment Modalities 13

Compugen Ltd. - Pipeline Products Glance 14

Compugen Ltd. - Early Stage Pipeline Products 14

Preclinical Products/Combination Treatment Modalities 14

Discovery Products/Combination Treatment Modalities 15

Compugen Ltd. - Drug Profiles 16

CGEN-15001 16

Product Description 16

Mechanism of Action 16

R&D Progress 16

CGEN-15021 18

Product Description 18

Mechanism of Action 18

R&D Progress 18

CGEN-15031 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

CGEN-15051 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

CGEN-15091 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

CGEN-25009 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

CGEN-856S 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

Monoclonal Antibody to Inhibit CGEN-15049 for Cancer 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

Monoclonal Antibody to Inhibit CGEN-15052 for Oncology 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

Monoclonal Antibody to Inhibit CGEN-15092 for Multiple Sclerosis 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

Monoclonal Antibody 1 to Inhibit CGEN-15029 for Oncology 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

Monoclonal Antibody 2 to Target B7/CD28 for Oncology 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

Monoclonal Antibody 3 to Target B7/CD28 for Oncology 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

Monoclonal Antibody 4 to Target B7/CD28 for Oncology 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

Monoclonal Antibody 5 to Target B7/CD28 for Oncology 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

Monoclonal Antibody Conjugate 2 for Oncology 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

Monoclonal Antibody Conjugates 1 for Oncology 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

Monoclonal Antibody for Cancer 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

Monoclonal Antibody to Inhibit CGEN-15027 for Oncology 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

Monoclonal Antibody to Target CGEN-928 for Multiple Myeloma 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

Compugen Ltd. - Pipeline Analysis 38

Compugen Ltd. - Pipeline Products by Target 38

Compugen Ltd. - Pipeline Products by Molecule Type 39

Compugen Ltd. - Pipeline Products by Mechanism of Action 40

Compugen Ltd. - Recent Pipeline Updates 41

Compugen Ltd. - Dormant Projects 45

Compugen Ltd. - Locations And Subsidiaries 46

Head Office 46

Other Locations & Subsidiaries 46

Appendix 47

Methodology 47

Coverage 47

Secondary Research 47

Primary Research 47

Expert Panel Validation 47

Contact Us 47

Disclaimer 48

List of Tables

List of Tables

Compugen Ltd., Key Information 6

Compugen Ltd., Key Facts 6

Compugen Ltd. – Pipeline by Indication, 2016 8

Compugen Ltd. – Pipeline by Stage of Development, 2016 10

Compugen Ltd. – Monotherapy Products in Pipeline, 2016 11

Compugen Ltd. – Out-Licensed Products in Pipeline, 2016 12

Compugen Ltd. – Out-Licensed Products/ Combination Treatment Modalities, 2016 13

Compugen Ltd. – Preclinical, 2016 14

Compugen Ltd. – Discovery, 2016 15

Compugen Ltd. – Pipeline by Target, 2016 38

Compugen Ltd. – Pipeline by Molecule Type, 2016 39

Compugen Ltd. – Pipeline Products by Mechanism of Action, 2016 40

Compugen Ltd. – Recent Pipeline Updates, 2016 41

Compugen Ltd. – Dormant Developmental Projects,2016 45

Compugen Ltd., Subsidiaries 46

List of Figures

List of Figures

Compugen Ltd. – Pipeline by Indication, 2016 8

Compugen Ltd. – Pipeline by Stage of Development, 2016 10

Compugen Ltd. – Monotherapy Products in Pipeline, 2016 11

Compugen Ltd. – Pipeline by Target, 2016 38

Compugen Ltd. – Pipeline by Molecule Type, 2016 39

Compugen Ltd. – Pipeline Products by Mechanism of Action, 2016 40


Discounts available for multiple report purchases.
+44 (0) 161 359 5414

Saved reports